Patents by Inventor Jill Detmer
Jill Detmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10968487Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.Type: GrantFiled: April 4, 2018Date of Patent: April 6, 2021Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
-
Publication number: 20180223377Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.Type: ApplicationFiled: April 4, 2018Publication date: August 9, 2018Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
-
Patent number: 9938584Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.Type: GrantFiled: January 31, 2017Date of Patent: April 10, 2018Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
-
Publication number: 20170137894Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.Type: ApplicationFiled: January 31, 2017Publication date: May 18, 2017Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
-
Patent number: 9605321Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.Type: GrantFiled: December 12, 2014Date of Patent: March 28, 2017Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
-
Publication number: 20150094231Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.Type: ApplicationFiled: December 12, 2014Publication date: April 2, 2015Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
-
Patent number: 8940486Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.Type: GrantFiled: January 4, 2011Date of Patent: January 27, 2015Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Jill Detmer, Arejas Uzgiris, Andy Ying
-
Publication number: 20120288863Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.Type: ApplicationFiled: January 4, 2011Publication date: November 15, 2012Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Jill Detmer, Arejas Uzgiris, Andy Ying
-
Patent number: 7993838Abstract: Provided are nucleic acid sequences that are used to prepare primers and probes that are used in a kinetic polymerase chain reaction (kPCR) assay to detect influenza viruses in a human or animal subject. The starting material for the kPCR assays may be DNA or RNA and the assays may be conducted in a singleplex assay to detect a single influenza virus or in a multiplex assay to detect multiple influenza viruses. The primers and probes have utility in the detection and quantification of type A and type B influenza viruses (INFA and INFB, respectively) and have been shown to be effective for the detection and quantification of all the known INFA subtypes, namely, H1, H2, H3, H4, H5, H6, H7, H8, and H9.Type: GrantFiled: April 20, 2007Date of Patent: August 9, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Jill Detmer, Charlene Bush-Donovan
-
Publication number: 20110003309Abstract: Provided are non-competitive internal controls for use in nucleic acid tests (NATs), which are obtained from the organisms Methanobacterium thermoautrophicum (MET) and Zea mays (Corn). The non-competitive internal controls have utility in DNA and RNA NATs selected from Influenza A, Influenza B, parainfluenza viruses 1 to 4 (PIV-1 to PIV-4), respiratory syncytial virus type A (RSV A), RSV B, human metapneumovirus (hMPV), Chlamydia trachomatis (CT), and Neisseria gonorrhea (GC), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Immunodeficiency Virus I (HIV-1), and Severe Acute Respiratory Syndrome (SARS).Type: ApplicationFiled: March 19, 2009Publication date: January 6, 2011Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Jill Detmer, Xiaoqiao Jiang, Minh Le, David Sherman
-
Publication number: 20100330548Abstract: Provided are nucleic acid sequences that are used to prepare primers and probes that are used in a kinetic polymerase chain reaction (kPCR) assay to detect influenza viruses in a human or animal subject. The starting material for the kPCR assays may be DNA or RNA and the assays may be conducted in a singleplex assay to detect a single influenza virus or in a multiplex assay to detect multiple influenza viruses. The primers and probes have utility in the detection and quantification of type A and type B influenza viruses (INFA and INFB, respectively) and have been shown to be effective for the detection and quantification of all the known INFA subtypes, namely, H1, H2, H3, H4, H5, H6, H7, H8, and H9.Type: ApplicationFiled: April 20, 2007Publication date: December 30, 2010Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Jill Detmer, Charlene Bush-Donovan
-
Publication number: 20100041019Abstract: Provided are nucleic acid primers and probes for use in diagnostic assays to screen for respiratory infections, such as respiratory syncytial virus (“RSV”) and human metapneumovirus (hMPV). The primers and probes may be used to screen for RSV or hMPV in a singleplex assay or they may be used in a multiplex assay to simultaneously screen for RSV and hMPV, or RSV and/or hMPV and any of the following viruses: influenza A, and influenza B, parainfluenza viruses, adenovirus, coronavirus, and rhinoviruses.Type: ApplicationFiled: October 2, 2007Publication date: February 18, 2010Inventors: Jill Detmer, Sukhwinder Sangha, Charlene Bush-Donovan